We aimed to assess whether whole-blood viscoelastic tests are useful to identify patients who are hypercoagulable and at increased risk of thromboembolism. Two investigators independently analyzed studies in the MEDLINE, EMBASE, and Cochrane controlled trial register databases to determine the ability of viscoelastic tests to identify a hypercoagulable state that is predictive of objectively proven thromboembolic events. Forty-one eligible studies, including 10,818 patients, were identified and subject to meta-analysis. The majority of the studies (n = 36, 88%) used the maximum clot strength to identify a hypercoagulable state which had a moderate ability to differentiate between patients who developed thromboembolic events and those who did not (area under the summary receiver operating characteristic [sROC] curve = 0.70, 95% confidence interval [CI]: 0.65-0.75). The pooled sensitivity, specificity, and diagnostic odds ratio to predict thromboembolism were 56% (95%CI: 44-67), 76% (95%CI: 67-83), and 3.6 (95%CI: 2.6-4.9), respectively. The predictive performance did not vary substantially between patient populations, and publication bias was not observed.
pecially in patients who have deranged coagulation parameters (eg, cirrhotic patients) or those after major surgery or severe trauma. 5, 6 It would be ideal if we can individualize anticoagulation for patients with different risks of thromboembolism, and differentiate between patients who are hypercoagulable and those who are at increased risk of bleeding. 7, 8 Although numerous clinical thromboembolic prediction scores have been developed, their reliability and applicability in different patient populations remain uncertain. [9] [10] [11] An alternative approach is to use biomarkers or coagulation blood tests to identify individuals who have a hypercoagulable state. Many novel coagulation biomarkers have been discovered, but most of these biomarkers are expensive, not widely available, and consequently, far from useful as a practical thromboembolic risk-stratifying tool. 12, 13 In vitro whole-blood viscoelastic tests-including thromboelastography (TEG ® ) or rotational thromboelastometry (ROTEM ® )-are widely used in many institutions to identify the mechanisms of bleeding in order to guide blood product transfusion for patients with active bleeding. 13 Emerging evidence suggests that an increase in in vitro clot strength, demonstrated on a viscoelastic test, reflects a hypercoagulable state and may be useful to identify patients who are at increased risk of thromboembolism. 14, 15 We hypothesized that whole-blood viscoelastic tests can differentiate between patients who are hypercoagulable with an increased risk of thromboembolism and those who are not. 16, 17 In this meta-analysis, we critically analyzed the literature to determine the ability of viscoelastic tests in identifying a hypercoagulable state that is predictive of objectively proven thromboembolic events. Specifically, we also assessed whether the commonly available viscoelastic tests have different abilities to predict arterial and venous thromboembolic events.
| MATERIALS AND METHODS

| Search strategy and selection criteria
This meta-analysis was conducted according to the PRISMA and "viscoelastic point-of-care," "thromboelastography," "thromboelastometry," "rotational thromboelastometry," "TEG," or "ROTEM" with "thrombosis," "venous thrombosis," "venous thromboembolism,"
"deep vein thrombosis," "pulmonary embolism," "prothrombotic," or "thrombotic." In this meta-analysis, only human studies, without any language restrictions, were included. The reference lists of related editorials, reviews, and original articles identified were searched for relevant studies, and the web sites of the International Network of Agencies of Health Technology Assessment in Health Care were also searched to ensure all suitable studies were included. The literature search was further updated in November 2017.
Although many viscoelastic tests are available, thromboelastography (TEG ® ) and rotational thromboelastometry (ROTEM ® ) tests are by far most widely available and used. As such, we have restricted our analysis to studies that used either of these 2 tests in this meta-analysis and compared their ability in predicting thromboembolic events.
| Data extraction and quality assessment
Two investigators independently examined the abstracts of the identified studies, followed by detail data extraction from the full texts if they were deemed eligible for this meta-analysis. Studies without data on thromboembolic events or definition for a hypercoagulable state by the whole-blood viscoelastic tests were excluded. The quality of the study was assessed according to the study design (eg, prospective vs retrospective, cohort study vs case-control study) and whether assessors of the thromboembolic events were blinded to the viscoelastic test results. When the reported results were unclear or only available in part, we contacted the corresponding authors of the identified studies to obtain additional data.
| Statistical analysis and outcomes of interest
Using a bivariate random-effects model, 18 the diagnostic odds ratio (how much greater the odds of developing either arterial or venous thromboembolic events for the people with a positive test result than for the people with a negative test result), sensitivity, specificity, and positive and negative likelihood ratios of the eligible studies were pooled. We used the area under the hierarchical summary receiver operating characteristic (sROC) curve to assess the overall performance of the viscoelastic tests in predicting objectively proven clinical thromboembolic events (by ultrasound, angiography, CT imaging or troponin level).
In determining the heterogeneity of the predictive ability of the viscoelastic tests, we used (a) sample size and (b) prevalence of thromboembolism as a covariate in a meta-regression to assess whether these factors were important in affecting the reported results. In addition, a threshold analysis by Moses-Shapiro-Littenberg model was used to assess whether the cut-points used to define hypercoagulability were related to the differences in the reported diagnostic odds ratios.
In addition, we conducted a number of subgroup and sensitivity analyses to explore possible reasons for heterogeneity. These included (a) restricting our analysis to only higher quality prospective studies in which assessors of the thromboembolic events were 
| RESULTS
| Search results
Of the 4963 studies identified in the databases, 41 studies from 14 countries, including 10,818 patients in a variety of clinical settings, met the inclusion criteria and were subject to meta-analysis ( Figure 1 ).
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A list of the studies excluded and the reasons for their exclusion are summarized in Appendix SIII.
Of the 41 studies included in the final analysis, 26 were prospective studies and most were cohort studies in which the viscoelastic test was performed before the thromboembolic events (n = 35, 85%). As for the case-control studies, the viscoelastic test was per- The characteristics of the included studies, including the diagnostic criteria used to define a hypercoagulable state, the prevalence of thromboembolic events, and type of patients assessed, are described in detail in Table 1 .
| Ability of viscoelastic tests to predict thromboembolic events
The overall ability of a hypercoagulable state, identified by a viscoelastic test, to predict thromboembolic events was moderate (the area under the sROC curve was 0.70, 95% confidence interval [CI]: 0.65-0.75) (Figure 2) . The pooled sensitivity, specificity, and diagnostic odds ratio of whole-blood viscoelastic tests to predict thromboembolic events were 56% (95%CI: 44-67), 76% (95%CI: 67-83), and 3.6 (95%CI: 2.6-4.9), respectively ( Figure 3) . The negative and positive likelihood ratios of the viscoelastic tests to predict thromboembolic events in each study and the overall pooled likelihood ratios are summarized in Appendix SIV. 
| Difference between predicting venous and arterial thromboembolic events
| Effects of sample size and prevalence of thromboembolic events on performance of the viscoelastic tests
The sample size (n = 16-2067) and prevalence (2.2% to 45% for prospective cohort studies) of the included studies varied substantially (Table 1) , but there was no significant association between either the sample size (slope of the regression line = 0, 95%CI: -0.000-0.001; P = .399) or prevalence of the thromboembolic events (slope of the regression line = 0.007, 95%CI: -0.018-0.031; P = .589) and the predictive ability of the viscoelastic tests (Appendices SV and SVI, respectively).
| Sensitivity analyses, threshold analysis, and publication bias
Overall, lower quality studies tended to yield more favorable results 
| DISCUSSION
This meta-analysis showed that whole-blood viscoelastic tests had a moderate ability to discriminate between patients who developed thromboembolism and those who did not in a variety of patient populations. These results are clinically relevant and require further discussion.
First, evidence suggests that whole-blood viscoelastic tests have the potential to inform the clinicians about the mechanisms of bleeding over and above the information provided by standard coagulation blood tests. 14, 63 Because a viscoelastic test assesses the clotting process of whole blood, including platelets, it has a potential to reflect bleeding or thrombotic tendency that is not measurable by activated partial thromboplastin time or prothrombin time, as both tests only use platelet-poor plasma. 63 Our results suggested that a viscoelastic hypercoagulable state is associated with an increased risk of thromboembolism, a 3.6-fold higher odd, compared to those without a hypercoagulable state. And as this was a diagnostic odds ratio, it would not be affected by the prevalence of the thromboembolism. 64 Indeed, our meta-regression did not show any association between the prevalence of thromboembolic events and reported diagnostic odds ratios of the included studies. sROC is also known to be robust to study heterogeneity, 65 and together with the consistency in the results of our multiple sensitivity analyses, the findings of this study are likely to be generalizable to a variety of patient cohorts with different prevalence of thromboembolism.
The relatively high specificity (76%) of a viscoelastic hypercoagulable state would suggest that such result has a low false-positive rate in identifying patients who would develop thromboembolism. Finally, we would like to acknowledge the limitations of this meta-analysis. Although we had included a large number of studies involving a variety of patient populations, the total number of patients analyzed was still limited, and hence, the overall pooled results were imprecise. The included studies also used different follow-up durations after the test to detect thromboembolic events, which could introduce heterogeneity because hypercoagulability due to most non-genetic causes may change, in one way or another, with time (eg, infection). We also noted that none of the included studies assessed the whole-blood viscoelastic tests in conjunction F I G U R E 4 The funnel plot, with the regression line in dashed line (P = .879), shows no obvious publication bias. ESS, effective sample size. ESS = (4 × n1 × n2)/(n1 + n2) where n1 = number of patients with thromboembolism and n2 = number of patients without thromboembolism in the study. Pooled diagnostic odds ratio from 41 studies was 3.6 (=0.56 in log 10 scale on the X-axis) and is defined by the vertical continuous line
